The role for osmotic agents in children with acute encephalopathies: a systematic review by Gwer, S et al.
RESEARCH ARTICLE Open Access
The role for osmotic agents in children with
acute encephalopathies: a systematic review
Samson Gwer
1,2*, Hellen Gatakaa
2,3, Leah Mwai
1,2, Richard Idro
1,4, Charles R Newton
1,5,6
Abstract
Background: Raised intracranial pressure (ICP) is known to complicate both traumatic and non-traumatic
encephalopathies. It impairs cerebral perfusion and may cause death due to global ischaemia and intracranial
herniation. Osmotic agents are widely used to control ICP. In children, guidelines for their use are mainly guided
by adult studies. We conducted this review to determine the current evidence of the effectiveness of osmotic
agents and their effect on resolution of coma and outcome in children with acute encephalopathy.
Methods: We searched several databases for published and unpublished studies in English and French languages,
between January 1966 and March 2009. We considered studies on the use of osmotic agents in children aged
between 0 and 16 years with acute encephalopathies. We examined reduction in intracranial pressure, time to
resolution of coma, and occurrence of neurological sequelae and death.
Results: We identified four randomized controlled trials, three prospective studies, two retrospective studies and
one case report. Hypertonic saline (HS) achieved greater reduction in intracranial pressure (ICP) compared to
mannitol and other fluids; normal saline or ringer’s lactate. This effect was sustained for longer when it was given
as continuous infusion. Boluses of glycerol and mannitol achieved transient reduction in ICP. Oral glycerol was
associated with lower mortality and neurological sequelae when compared to placebo in children with acute
bacterial meningitis. HS was associated with lower mortality when compared to mannitol in children with non-
traumatic encephalopathies.
Conclusion: HS appears to achieve a greater reduction in ICP than other osmotic agents. Oral glycerol seems to
improve outcome among children with acute bacterial meningitis. A sustained reduction in ICP is desirable and
could be achieved by modifying the modes and rates of administration of these osmotic agents, but these factors
need further investigation.
Background
Raised intracranial pressure (ICP) is a recognized feature
of both traumatic and non-traumatic encephalopathies
[1-4]. It impairs cerebral perfusion pressure (CPP), lead-
ing to ischaemia, and may cause death by compressing
the brainstem during intracranial herniation. Raised ICP
has consistently been shown to be an important deter-
minant of outcome in children with central nervous sys-
tem (CNS) infections and traumatic brain injuries (TBI)
[1,4,5]. Management of raised ICP is aimed at optimiz-
ing CPP and oxygen supply to the brain in addition to
reducing ICP. Methods to reduce ICP include postural
changes, temperature regulation, hyperventilation,
sedation, drainage of cerebro-spinal fluid, operative
decompression, and the most widely used, osmotherapy
[6-8].
Osmotherapy entails the use of pharmacologically
i n e r ts u b s t a n c e st h a ti n c r e a s et h eo s m o t i cp r e s s u r eo f
plasma, promoting movement of water from interstitial
space to vascular space [9]. Osmotic agents include
mannitol, urea, sorbitol, glycerol and hypertonic saline
(HS). Although these agents act mainly by reducing ICP
via an osmotic gradient, they may have other beneficial
effects. Thus, mannitol has been shown to scavenge
reactive oxygen species [10], reduce the viscosity of
blood, improving its flow through the circulation [11],
and cause vasoconstriction, reducing cerebral blood
volume [12]. Hypertonic saline is an effective volume
expander which improves systemic haemodynamics and
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shown to enhance cerebral microcirculation by reducing
adhesions of polymorphonuclear cells and by stimulating
local release of nitric oxide [14].
Guidelines for use of osmotic agents have been devel-
oped from adult TBI studies. However, these have been
adapted for children with minimal evidence obtained
directly from children with TBI. Among children with
non-traumatic encephalopathies, guidelines are virtually
non-existent. In a postal survey of raised ICP manage-
ment protocols in UK hospitals, practices varied greatly
between hospitals [15]. Monitoring for patients with
non-traumatic encephalopathy was seldom considered
and thus, little consideration was given for use of osmo-
tic agents in this group.
We performed this review to determine the best avail-
able evidence on the effectiveness of various osmotic
agents and their effect on resolution of coma and out-
come (neurological sequelae and mortality) in children
with acute encephalopathies.
Method
This review examines the effectiveness of osmotic agents
in reducing ICP in children with acute encephalopathies
and, the effect of osmotic agents on resolution of coma
and clinical outcome (neurological sequelae and mortal-
ity) in children with acute encephalopathies.
Inclusion criteria
We searched published and unpublished studies in the
English and French languages between January 1966 and
March 2009. We reviewed randomized controlled trials
with the aim of performing a meta-analysis. In addition,
we examined quasi- and non-randomized clinical trials,
case control, cohort, and before and after studies, case
series, and case reports, for consideration in a narrative
summary.
We evaluated studies that included children aged
between 0 and 16 years with acute traumatic and non-
traumatic encephalopathies, characterized by altered
consciousness. Agents included in our search were man-
nitol, hypertonic saline, urea, sorbitol and glycerol. The
primary outcome measure was reduction in ICP. Sec-
ondary outcome measures were resolution of coma and
clinical outcome (neurological sequelae and death).
Search Strategy
We searched Pubmed, Cochrane library, EMBASE and
cumulative index to nursing and allied health literature
(CINAHL). Other databases included were current con-
trolled trials, the trials register for promoting health
interventions (TRoPHI), Australian clinical trials registry
(ACTR), clinical medicine net prints collection, Bando-
lier evidence based health care, and the center for
clinical trials and evidence-based healthcare at Brown
medical school. The search databases for unpublished
studies and grey literature were dissertation abstracts
international, the World Health Organization library,
Agency for Healthcare Research and Quality, Grey lit-
erature report, National Library of Medicine, theses
Canada portal, Proquest digital theses, Australasian digi-
tal theses program and the British library. The initial
search analyzed the text words contained in the title
and abstract, and the index terms used to describe the
articles. A second search that used all identified key-
words and index terms, individually and in combina-
tions, was applied. The reference list of all identified
reports and articles were then searched for additional
studies. In our search in Pubmed, we applied the search
phrase “(mannitol [MeSH] OR hypertonic saline
[MeSH] OR urea [MeSH] OR sorbitol [MeSH] OR gly-
cerol [MeSH]) AND (hepatic encephalopathy [MeSH]
OR malaria, cerebral [MeSH] OR meningitis [MeSH]
OR encephalitis [MeSH] OR brain injuries [MeSH] OR
head injuries [MeSH] OR coma [MeSH] OR intracranial
hypertension [MeSH])” and limited it to children, the
English and French languages, and the duration between
1
st of January 1966 and 31
st March 2009, and children.”
Assessment of studies
The papers selected for retrieval were assessed by two
independent reviewers for methodological validity prior
to inclusion in the review. We used the standardized
critical appraisal instruments from the Joanna Briggs
Institute Meta-Analysis of Statistics Assessment and
Review Instrument (JBI-MAStARI) Critical Appraisal
tool [16]. Any disagreements between the reviewers
were resolved through discussion, or with a third
reviewer. We extracted data using the standardized JBI
data extraction tool [16]. All data were entered twice
and discrepancies resolved. We considered quantitative
studies for pooling for statistical meta-analysis. Relative
risk and their 95% confidence intervals (95%CI) were
calculated for analysis. Other findings were presented in
a narrative form.
The protocol that guided this review is available, on
request, from the review protocols section of the Joanna
Briggs institute website; http://www.joannabriggs.edu.au/
pubs/systematic_reviews_prot.php
Results
Our search of the databases revealed 291 records. We
identified 20 studies that met our review criteria. We
critically appraised them using the JBI-MASTARI
assessment tool and excluded 10 studies. The different
phases of the review are summarized in figure 1. Four of
the studies excluded did not provide any data or infor-
mation on the relationship between the interventions
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included children and adults but data on children were
not provided separately nor could we obtain this infor-
mation from the authors [21-23]. Two other studies
were excluded for other reasons [24,25] (Table 1).
We included four randomized controlled trials (RCTs)
[26-29], one of which was a cross-over trial [26], three
prospective observational studies [1,30,31], two retro-
spective studies [32,33], and one case report [34]. Out of
these, four studies involved patients with non-traumatic
encephalopathies [1,27,28,32]. The characteristics of
these studies (participants, interventions, comparisons,
outcomes, and study design) are summarized in addi-
tional file 1. Among the clinical trials, assignment of
treatment was random in all the studies, but in two
studies, the allocation to treatment groups was not con-
cealed from the investigators [26,29]. We assessed each
study according to its study design as shown in tables 2,
3 and 4.
Intracranial Pressure
ICP was monitored in 7 studies; 2 RCTs [26,29], 4
observational studies [1,30,31,33] and one case report
[34]. In one RCT, ringer’s lactate was compared to HS
for resuscitation of 32 children with traumatic brain
injuries [29]. More interventions for raised ICP were
used in the Ringer’s lactate group compared to the HS
group (P < 0.01) [29]. However, there was no significant
difference in the mean ICPs between the two groups
after the interventions. In a crossover trial that included
Figure 1 Flow of information through the systematic review.
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the initial ICP with use of HS(P = 0.003) compared to
normal saline (P = 0.32) [26].
Hypertonic saline given as a continuous infusion in a
study of 10 children with TBI achieved a significant and
sustained reduction of ICP that was maintained over 72
hours (P < 0.01) [30]. These children had raised ICP
that was refractory to other management strategies
including the use of bolus infusions of mannitol. Among
23 children with cerebral malaria, a dose-response effect
with use of boluses of mannitol was observed in moder-
ately raised ICP (ICP > 20 mmHg, CPP < 50 mmHg)
but not with severely raised ICP (ICP > 40 mmHg, CPP
< 40 mmHg) [1]. In a study of 3 children with TBI, oral
glycerol was shown to reduce ICP by at least 50% within
the first half hour of administration and maximally after
60 minutes [31]. This reduction was not maintained
beyond 90 minutes. A case report of two children with
TBI showed a dose response relationship between both
HS and mannitol, and ICP [34]. However, mannitol
appeared to cause a reduction in CPP.
All the five studies that investigated HS
[26,29,30,33,34] demonstrated a dose-response effect on
ICP irrespective of the saline concentrations.
Mortality
All the included studies reported mortality. However, in
examining mortality, we only analyzed the RCTs since
they were the only studies that had groups for compari-
son. The four RCTs [26-29] identified were heteroge-
neous in relation to the interventions used and could not
be pooled for meta-analysis. In one multicentre trial on
654 children with bacterial meningitis, the mortality was
lower in those given glycerol compared to placebo (RR
0.64 95%CI 0.54, 0.76) [28] and, in children given glycerol
and dexamethasone combination compared to placebo
(RR 0.79 95%CI 0.68, 0.92) [28] (Figure 2). Our own ana-
lysis of this data suggests a lower mortality with use of
glycerol and dexamethasone combination compared to
glycerol alone (RR 0.81 95% CI 0.67, 0.98). Another trial
comparing the use of HS and ringer’s lactate as resuscita-
tive fluids in 32 children with TBI reported only 2 deaths
which occurred in children receiving ringer’s lactate [29].
Among 156 children with cerebral malaria (CM), there
was no observed difference in mortality when a single
bolus of mannitol was administered compared to normal
saline (RR 0.81 95%CI 0.60, 1.09) [27]; this trial was how-
ever not powered to detect a difference in mortality. In a
clinical series of children with non-traumatic encephalo-
pathies, there was less mortality with use of HS compared
to mannitol (RR 0.48 95%CI 0.34, 0.67) [32].
Table 1 Reason for exclusion of studies
Study Reason for exclusion
Prabhakaran
2004 [19]
The paper did not report on effect of the
intervention, mannitol, on ICP or outcome
Vialet 2003 [23] The study provides combined results for adults and
children, and the data for children could not be
extracted
Kingston 1971
[18]
There is little information on the characteristics of the
participants. There is no data provided on the effect
of the intervention, urea, on ICP or outcome
Cruz 2002 [17] The use of the intervention, mannitol, was not clearly
evaluated and the study does not demonstrate the
relationship between mannitol use and outcome
James 1977 [22] The study provides combined the results for adults
and children, and the data on children could not be
extracted.
James 1980 [21] The study provides combined the results for adults
and children, and the data on children could not be
extracted.
MacDonald
1982 [25]
Reason for selective data presentation not given and
administration of both treatments not clearly
described
Marshall 1978
[24]
Age of subjects is not given and unclear statistical
methods have been used
Mickell 1977
[20]
The relationship between the intervention and ICP or
outcome is not described
Procaccio 1991
[36]
The study included a heterogeneous age group of
patients that is not comparable and in whom
standard treatment was not provided to all
Table 2 Methodological assessment of clinical trials
Study Fisher
1992 [26]
Namutangula
2007 [27]
Peltola
2007 [28]
Simma
1998 [29]
Was the assignment to treatment groups truly random? Y Y Y Y
Were participants blinded to treatment allocation? N Y Y Y
Was allocation to treatment groups concealed from the allocator? U Y Y N
Were the outcomes of people who withdrew described and included in the analysis? Y Y Y Y
Were those assessing outcomes blind to the treatment allocation? U Y Y N
Were the control and treatment groups comparable at entry? N Y Y Y
Were the groups treated identically other than for the named interventions? Y Y Y Y
Were outcomes measured in the same way for all groups? Y Y Y Y
Were outcomes measured in a reliable way? Y Y Y Y
Was appropriate statistical analysis used? Y Y Y Y
* Y = Yes, N = No, U = Unclear
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Four studies reported on neurological sequelae
[1,28,30,33], but only one of these studies was a clinical
trial [28]. In this trial examining the use of glycerol and
dexamethasone in 654 children with bacterial meningi-
tis, poor outcome (defined as severe neurological seque-
lae and profound hearing loss) was lower in the glycerol
group (RR 0.58 95%CI 0.50, 0.67) and the glycerol and
dexamethasone combination (RR 0.55 95%CI 0.47, 0.65)
compared to placebo [28]. This lower risk was similarly
observed when severe neurological sequelae were exam-
ined alone. No significant differences were observed
between the glycerol and the glycerol and dexametha-
sone combination.
Resolution of Coma
Only one study, a clinical tri a lo fm a n n i t o lo nc h i l d r e n
with CM, examined resolution of coma as an outcome
measure [27]. There was no difference between use of
mannitol and placebo in coma resolution [median (IQR
duration 20.5 (14.1-53.4) and 18.9 (10.0-38.0) hours
respectively (p = 0.11)].
Discussion
We identified four RCTs, one of which was on children
with non-traumatic encephalopathies. Each trial com-
pared different agents and could not be pooled for
meta-analysis. We examined 3 prospective observational
studies, 2 retrospective studies and 1 case report. In our
evaluation, HS appeared to achieve greater reduction in
ICP than other osmotic agents. Oral glycerol was asso-
ciated with less mortality and neurological sequelae
when compared to placebo among children with acute
bacterial meningitis. The only study that examined reso-
lution of coma did not show any difference between the
osmotic agent, mannitol, and placebo.
There was a dose response in the reduction of ICP
with use of all the agents examined. However, ICP is a
dynamic entity and single measurements on admission
indicating raised ICP do not predict clinical outcome
[1]. The analysis of ICP measurements therefore often
consists of determining the duration of time that ICP is
above a certain threshold [35]. It is desirable that inter-
ventions result in sustained reductions in ICP. And so,
whilst all agents in the studies reviewed exhibited a dose
response effect, this was transient in a number of cases.
Continuous infusions of HS appeared to achieve sus-
tained reduction in ICP. However, the advantage of dif-
ferent rates of administration can only be reliably
investigated in clinical trials that specifically investigate
the different modes and rates of administration of a par-
ticular intervention.
Hypertonic saline was shown to reduce ICP more than
either normal saline [26] or ringer’s lactate solutions
[29]. When compared to mannitol, HS maintained or
improved CPP, an important determinant of neurologi-
cal outcome [34]. This effect is particularly important in
Table 3 Methodological assessment of cohort study
Study Yildizdas
2006
[32]
Is sample representative of patients in the populations as a
whole?
Y
Are the patients at a similar point in the course of their
condition/illness?
Y
Has bias been minimized in relation to selection of cases
and of controls?
U
Are confounding factors identified and strategies to deal
with them stated?
N
Are outcomes assessed using objective criteria? Y
Was follow up carried out over a sufficient time period? Y
Were the outcomes of people who withdrew described and
included in the analysis?
Y
Were outcomes measured in a reliable way? Y
Was appropriate statistical analysis used? Y
* Y = Yes, N = No, U = Unclear
Table 4 Methodological Assessment of descriptive and case series studies
Study Berger 2002
[34]
Peterson
2000
[33]
Khanna
2000
[30]
Newton
1997
[1]
Wald
1982
[31]
Was study based on a random or pseudo-random sample? N N N N N
Were the criteria for inclusion in the sample clearly defined? Y Y Y Y N
Were confounding factors identified and strategies to deal with them stated? N N U U U
Were outcomes assessed using objective criteria? Y Y Y Y Y
If comparisons were being made, were there sufficient descriptions of the groups? Y Y Y Y Y
Was follow up carried out over a sufficient time period? Y Y Y Y Y
Were the outcomes of people who withdrew described and included in the
analysis?
Y Y YYY
Were outcomes measures in a reliable way? Y Y Y Y Y
Was appropriate statistical analysis used? Y Y Y Y Y
* Y = Yes, N = No, U = Unclear
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such as TBI and cerebral malaria. Theoretically, HS as a
crystalloid may equilibrate freely throughout brain tissue
in encephalopathies associated with impairment of the
blood brain barrier such as meningitis, thus aggravating
ICP. However there is little evidence of this phenom-
enon in the studies that we reviewed.
There was a lower relative risk of death with HS com-
pared to mannitol [32], and with oral glycerol or a com-
bination of oral glycerol and dexamethasone compared
to placebo [28]. In the latter trial, glycerol, either alone
or combined with dexamethasone, was associated with
fewer neurological sequelae compared to placebo. There
appeared to be less mortality when glycerol was used in
combination with dexamethasone compared to glycerol
used alone. Glycerol, given orally, allows for a conveni-
ent mode of administration considering resource poor
settings. This trial was carried out across 10 institutions
in different countries and the consistency of care is
likely to have been difficult to maintain. Studies needed
to examine effects of osmotic agents on neurological
outcome would require large samples sizes and longer
durations of follow up than those of the studies we
examined.
We restricted our search to studies that were pub-
lished in the English and French languages after 1966,
potentially missing out on a number of studies in other
languages. However, it is unlikely that a search of litera-
ture before 1966 could have yielded adequately reported
studies on children. Most of the studies that we have
included are observational studies and thus limit the
validity of our analysis.
In one study that we included [29], the osmotic agent
was examined for use as a resuscitative fluid, not for
treatment of ICP. Nevertheless, this study provided data
on the use of osmotic agents and suggested a more
effective mode of administration of osmotic agents, sup-
porting continuous rather than bolus infusions. We have
included one study that had a mixed population of chil-
dren and adults [31]. In this study, some of the data on
children is provided separately. In another study, young
infants were also recruited but their results were not
analysed separately [32]. Young infants have an imma-
ture nervous system and a patent anterior fontanelle,
and the dynamics of ICP is different from that of older
children. In addition, scoring them for coma using a
similar scale as for older children could be misleading.
Another study investigated children with a varied aetiol-
ogy of acute encephalopathies [36]. Even so, the patho-
physiology of raised ICP appears to be similar
irrespective of aetiology.
A clinical trial examining the use of oral glycerol and
rectal paracetamol among children with meningitis in
Malawi (ISRCTN70121840) is ongoing and when com-
plete, may provide more insight on the use of osmotic
agents in children.
Conclusion
The review supports the use of oral glycerol in children
with acute bacterial meningitis and the use of
Figure 2 Risk ratios of death with different osmotic agents.
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encephalopathies. However, the evidence presented is
not sufficient to provide guidelines. Further clinical trials
are needed to examine the safest and most efficacious
concentrations of the various agents, particularly hyper-
tonic saline. Such studies will also guide on the appro-
priate routes of administrations and the optimum rates
of administration of these agents. Multi-centre trials
may be necessary to achieve adequate sample sizes.
Additional file 1: Characteristics of included studies. This table
provides a summary of the characteristics of included studies, including
details regarding participants, interventions, comparison groups,
outcome, and the study design. The authors’ conclusions and the
reviewers’ comments on each paper are also included
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